Chemical Matricectomy: A Modern Solution for Nail Issues!
Published: Jul 21, 2024
Chemical matricectomy is a game-changer for those dealing with chronic ingrown nails. Let's explore how this therapy works.
Contents
What is Chemical Matricectomy?
Chemical matricectomy involves the use of chemicals like phenol to destroy the nail matrix, preventing future nail growth. This procedure is often recommended for chronic or recurrent ingrown toenails. It's a less invasive alternative to surgical nail removal, offering effective results with minimal downtime.
The Benefits of This Procedure
Chemical matricectomy has several advantages over traditional surgical methods. It is less painful, has a shorter recovery time, and reduces the risk of recurrence. The procedure allows patients to return to their normal activities quickly, typically within a few days. Moreover, it poses a lower risk of infection compared to other techniques.

What to Expect During the Procedure
The chemical matricectomy procedure is straightforward and usually performed under local anesthesia. The affected area is treated with a chemical agent, such as phenol, to effectively stop nail growth. Patients may experience some discharge and mild discomfort post-procedure, but these symptoms typically resolve quickly.
Frequently Asked Questions
The procedure itself is not painful due to local anesthesia.
It significantly reduces recurrence rates of ingrown nails.
Most people return to normal activities in a few days.
Key Takeaways
Chemical matricectomy offers a modern, efficient solution for dealing with chronic nail issues.
Discover if chemical matricectomy is right for you by consulting with Doctronic today!Related Articles
References
Romero-Pérez D, Betlloch-Mas I, Encabo-Durán B. Onychocryptosis: a long-term retrospective and comparative follow-up study of surgical and phenol chemical matricectomy in 520 procedures. Int J Dermatol 2017; 56:221.
Bostanci S, Ekmekçi P, Gürgey E. Chemical matricectomy with phenol for the treatment of ingrowing toenail: a review of the literature and follow-up of 172 treated patients. Acta Derm Venereol 2001; 81:181.
Always discuss health information with your healthcare provider.